Examples of using Differences were observed in English and their translations into Romanian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
No gender differences were observed.
The pharmacokinetics of atazanavir were evaluated in healthy adult volunteers andin HIV-infected patients; significant differences were observed between the two groups.
No substantial differences were observed between the two groups.
Similarly, no plasma clearance differences were observed.
These differences were observed in each different age group studied.
No clinically relevant gender differences were observed in the REPLACE study.
No differences were observed in the other serological markers.
No clinically significant differences were observed between men and women.
No differences were observed in the time-course pre-dialysis blood pressures(BPs);
No clinically relevant gender differences were observed in clinical studies.
No age differences were observed with respect to response to the ADHD-RS-IV.
No gender or age-related pharmacokinetic differences were observed after correction for body weight.
(b, d) No differences were observed in post-dialysis SBP or DDD between the two groups.
In a paediatric pharmacokinetic study, andbased on very limited sampling, minor differences were observed for artenimol pharmacokinetics between the paediatric and adult populations.
No differences were observed in quality of life between the treatment and placebo arms.
The pharmacokinetics of Pixuvri was dose-independent in the 3 mg/m2 to105 mg/m2 dose range and no substantial differences were observed when the medicinal product was given as a single agent or in combination studies.
No differences were observed between the cell-culture and the comparator egg-derived vaccine.
The pharmacokinetic properties of amprenavir following co-administration of Telzir with ritonavir have been evaluated in healthy adult subjects andHIV-infected patients and no substantial differences were observed between these two groups.
No gender-related differences were observed in the pharmacokinetics of palifermin.
Differences were observed at each visit after 4 weeks(duloxetine 54%, and placebo 22%), 8 weeks(52% and 29%), and 12 weeks(52% and 33%) of medication.
In this small number of patients no differences were observed in either pharmacodynamic or pharmacokinetic parameters.
No major differences were observed for safety and efficacy in patients≥65 years of age as compared to adults aged 18 to 65 years.
However, in study US301 no significant differences were observed between leflunomide and methotrexate in the primary efficacy parameters.
No differences were observed in the in vitro activity of retapamulin versus S. aureus whether the isolates were susceptible or resistant to methicillin.
Regarding the whole body reaction time, no significant differences were observed before and after the 4-week period in the case of the PW group, as seen in Figure 5B.
No statistical differences were observed between treatment groups for Global Quality of Life using EORTC QLQ-C30 and EuroQoL EQ-5D.
Gender- No gender differences were observed after adjustment for body weight.
No pharmacokinetic differences were observed between Japanese and Caucasian healthy volunteers.
No statistical differences were observed between treatment groups for Global Quality of Life.
No significant pharmacokinetic differences were observed between subjects with normal renal function and subjects with renal impairment.